Molecular Data Integration for Precision Medicine in Breast Cancer
summary
A multi-arm adaptive platform called ISPY2 adaptive trial runs on newly diagnosed high‑risk breast cancer with a six‑month neoadjuvant endpoint, 1,700 screened and ~1,000 enrolled, and >30,000 biospecimens collected. An early PARP inhibitor arm graduates after 72 patients; in triple‑negative patients pCR rises from 27% (control) to 56% with treatment and to 79% when combined with two genomic/proliferation biomarkers, showing fast, biomarker‑driven drug selection that can shorten trials.
AI-written summary · about
chapters (8)
- 0:00Start
- 3:33Strategies for High Risk Breast Cancers
- 9:26I-SPY 2 Adaptive Trial Design
- 14:44Veliparib/Carboplatin GRADUATES in the Triple Negative Signature
- 16:13Testing Novel Companion Diagnostics
- 17:09Tissue Use - Pre-Treatment cores for Biomarkers
- 19:56DNA repair biomarkers and association with response to V/C
- 26:04Real World Context: Discovery to Diagnostics to Patient Care
related talks
30mUnlocking the Genome: Exploring the Potential of CRISPR/Cas9
21mKeynote: EPI, The European Approach for Exascale Ages. The Road Toward Sovereignty
08mScience & Industrial Innovation With Quantum-Accelerated Highperformance Computers
21mEnabling the next level of scientific exploration
26mTed Willke, Senior Principal Engineer, Intel Labs
11mScience & Industrial Innovation With Quantum-Accelerated Highperformance Computers
27mPractical Quantum Computing
18m"Dark Side" of Data: The NSA ThinThread Tale